Data show longer-term efficacy of teprotumumab in severe, less severe thyroid eye disease

Additional data from the OPTIC-X extension trial and pooled analysis of phase 2 and 3 trial data confirm the efficacy of teprotumumab for the treatment of thyroid eye disease in the longer term and at different degrees of disease severity.
Tepezza (teprotumumab, Horizon Therapeutics) is a human monoclonal antibody inhibitor of insulin-like growth factor-1 receptor (IGF-1R) that halts the IGF-1R/thyroid-stimulating hormone receptor signaling at the source of the thyroid eye disease, reducing inflammation and reversing retro-orbital tissue expansion and hyaluronan production. The phase 3 OPTIC

Full Story →